UK Trade & Investment — the business development arm of the British Consulate — invited DevicePharm CEO & Chief Strategy Officer, Clay Wilemon, to present to UK medical firms during a February conference.
Healthcare reform is changing the way that healthcare marketers think about everything from clinical trials to product launches. New payment models, new delivery models, and HEOR mandates are all creating major changes in marketing focus for medical device, biotech, pharmaceutical, and medical diagnostics companies.
OCTANe launched the 10th annual Medical Device & Investor Forum on November 2, 2015 at the Hotel Irvine by introducing an expanded vision for Orange County’s technology industry accelerator. The presentation included an introduction of the expanded brand scope and new branding elements by DevicePharm CEO & Chief Strategy Officer, Clay Wilemon.
What if you could focus your marketing plans and messaging only on the people who were actually going to buy your product or service?” This was the question posed by Clay Wilemon, DevicePharm CEO & Chief Strategy Officer, to an enthusiastic audience in San Diego during the September Device Alliance meeting.
The reality is that using predictive analytics in market research is providing a more precise way of targeting, messaging, and selling to the customers who are actually going to buy your products.
The OCTANe Ophthalmology Summit is a unique convocation of ophthalmology executives, researchers, entrepreneurs, investors, physicians, and surgeons. Held each year in Orange County, CA, the global ophthalmic industry hub, this event provides an important opportunity for innovators to gather and share ideas about the growth and future of this important medical industry segment.
A recent Medical Marketing & Media article indicated that 55% of pharmaceutical companies are either partially or strongly dissatisfied with their multi-channel marketing efforts. The article went on to quote that, “When integrated across an organization and executed properly, multi-channel campaigns can boost top-line growth by more than 10% and reduce overall promotional costs by 10% to 25%.” So where is the disconnect between multi-channel marketing effectiveness and multi-channel marketing dissatisfaction?
Imagine looking at market research results and seeing that a large population of consumers wanted to pay a relatively low price for a new elective medical procedure. Just a few years ago, this would have been a cut-and-dry result leading to a lower price. However, using an advanced predictive analytics platform powered by Compellon, DevicePharm was able to dig deeper and determine that the actionable market was actually bigger with the higher price point.
“Do we really need sales reps to support medical devices?” This question has been asked by surgeons, medical device CEOs, and hospital administrators for years. Recently, however, that philosophical question moved from theory to practice in a bold move by Smith & Nephew.
In the movie the Wizard of Oz, Dorothy famously exclaimed, “Lions, and tigers, and bears, oh my!” Today’s equivalent would be, “Apple, and Android, and Apps, oh my!”
At DevicePharm, we are having increasingly complex discussions with our clients about web and mobile media platforms. The lines between phones, tablets, and computers as well as apps, and app-like web solutions continue to blur. And the lines between perception and reality, in terms of what consumers are actually doing online, are in a constant state of flux. It makes Dorothy’s animal issue pale by comparison.
We have all seen a research report that defines customer behaviors, the opinions of a segment of the market about a topic, or even how a population reacts to a specific message. That is certainly helpful to marketers, but the big question still remains, “What about the buyers?”